Location Directory

Clinical trials in San Francisco, California

This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5145

Shown on this page

Current sort

Institutions in San Francisco

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UCSF

Live official records

Open in full search

Conditions: Adenovirus Infections
Interventions: cidofovir, Brincidofovir; Drug
Lead sponsor: SymBio Pharmaceuticals; Industry
Eligibility: 2 Months and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more

Conditions: Cancer
Interventions: Multi-Cancer Early Detection Test (Galleri®); Device
Lead sponsor: GRAIL, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 72
States / cities: Fort Smith, Arkansas • Auburn, California • Davis, California + 51 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
Interventions: Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration, Quality-of-Life Assessment; Other · Behavioral
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 526
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more

Conditions: Open Midline Laparotomy
Interventions: Phasix™ Mesh; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 17 more

Conditions: Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infections (STIs)
Interventions: Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling; Drug · Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 29 Years · Female only
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Frailty, Lung Tranplant Candidate
Interventions: XFIT; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 216
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more

Conditions: Liver Diseases, Alcohol Use Disorder
Interventions: Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC); Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Newport Beach, California • San Francisco, California • Miami, Florida + 13 more

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review; Procedure · Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • The Bronx, New York • Durham, North Carolina

Clinical trials in San Francisco, California

Filter and sort this location

Institutions in San Francisco

Live official records

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Galleri® in the Medicare Population.

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

Exercise-based Frailty Intervention in Lung Transplantation (XFIT)

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Safety Study of MucoCept-CVN

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer